 |
 |
In this week's CEO Bulletin there is a consultation paper on proposed funding mechanisms for specialist pathology services. Comments to the DOH are required by 17th June. The papers are on: http://www.doh.gov.uk/cebulletin6june.htm This could have a significant bearing on allocations to labs offering rare assays or who have specialist expertise. The initial proposal was to disperse all funds to PCTs which posed the danger of undermining the the long established networks of specialist labs. The current proposal includes the suggestion that all specialist testing should be seen as a tertiary referral controlled by the laboratory with primary responsibility for the patient. The matter of where the funding is held in PCTs or SHAs remains open. I believe that this is an opportunity for the profession to steer the DOH toward a more rational approach to lab funding. Don't miss the opportunity to respond. Rick Jones I ------- End of forwarded message ------- Dr Rick Jones Director of Chemical Pathology and Immunology Pathology Directorate Leeds Teaching Hospitals Trust Tel:(44)-113-233-5677 Fax:(44)-113-233-5672 http://www.acb.org.uk http://www.yichi.org.uk http://www.leedsteachinghospitals.com http://www.leeds.ac.uk/rdinfo //Winner - Best Health Database HC99 ------ACB discussion List Information-------- This is an open discussion list for the academic and clinical community working in clinical biochemistry. Please note, archived messages are public and can be viewed via the internet. Views expressed are those of the individual and they are responsible for all message content. ACB Web Site http://www.acb.org.uk List Archives http://www.jiscmail.ac.uk/lists/ACB-CLIN-CHEM-GEN.html List Instructions (How to leave etc.) http://www.jiscmail.ac.uk/